首页> 外文期刊>Basic Research in Cardiology >Microembolization and myonecrosis during elective percutaneous coronary interventions in diabetic patients: an intracoronary Doppler ultrasound study with 2-year clinical follow-up
【24h】

Microembolization and myonecrosis during elective percutaneous coronary interventions in diabetic patients: an intracoronary Doppler ultrasound study with 2-year clinical follow-up

机译:糖尿病患者选择性经皮冠状动脉介入治疗期间的微栓塞和心肌坏死:一项为期2年的临床随访的冠状动脉内多普勒超声研究

获取原文
获取原文并翻译 | 示例
           

摘要

Elevation of cardiac troponin I (cTnI) is a well-known complication after percutaneous coronary interventions (PCI). The aims of this study were to quantify the extent of coronary microembolization during elective PCI, to identify predisposing anatomical and procedural factors, and to evaluate its impact on long-term outcome in diabetic patients with a high cardiovascular risk. 48 patients (pts, median 66.7 years) with type 2 diabetes and coronary artery disease underwent elective PCI with stenting to treat single-vessel lesions. Real-time microembolization during PCI (“HITS”) was detected by an intracoronary Doppler guide wire. Peak levels of cTnI were measured within 24 h after PCI. Pts were followed for 2 years to record major cardiac events (MACE: death, myocardial infarction, revascularization of target and non-target vessels). In 47 patients microemboli were detected during PCI. Nineteen patients showed pathologic cTnI elevation (0.13–28.9, median 0.39 μg/l). The amount of HITS correlated with cTnI levels (r = 0.43, p = 0.003), but not with other clinical or angiographic data. Within 2 years MACE were detected in 9 patients, who had significantly more microemboli (15.4 ± 11.8 vs. 28.2 ± 16.0 HITS; p = 0.009, OR 1.07; 95 % CI 1.011–1.13) during PCI. HITS >23, but not cTnI elevation, predicted later MACE (ROC analysis, p = 0.025). A high amount of microembolization during elective PCI in diabetic patients appears to be an indicator of greater atherosclerotic burden and accelerated coronary artery disease progression, associated with acute biomarker elevation and adverse long-term outcomes.
机译:心脏肌钙蛋白I(cTnI)升高是经皮冠状动脉介入治疗(PCI)后的众所周知的并发症。这项研究的目的是量化择期PCI期间冠状动脉微栓塞的程度,确定易患的解剖和程序因素,并评估其对高心血管风险糖尿病患者长期预后的影响。 48例2型糖尿病和冠状动脉疾病患者(pts,中位数66.7岁)接受了选择性PCI支架置入术治疗单支血管病变。通过冠状动脉内多普勒导丝检测PCI(HITS)期间的实时微栓塞。在PCI后24小时内测量了cTnI的峰值水平。随访2年以记录主要心脏事件(MACE:死亡,心肌梗塞,靶血管和非靶血管的血运重建)。 47例患者在PCI期间检测到微栓子。 19名患者表现出病理性cTnI升高(0.13–28.9,中位数0.39μg/ l)。 HITS的数量与cTnI水平相关(r = 0.43,p = 0.003),但与其他临床或血管造影数据无关。在2年内,检测到9例患者的MACE,PCI期间微栓塞的发生率明显更高(15.4±11.8 vs. 28.2±16.0 HITS; p = 0.009,OR 1.07; 95%CI 1.011–1.13)。 HITS> 23,而不是cTnI升高,则预测稍后发生MACE(ROC分析,p = 0.025)。糖尿病患者在择期PCI期间大量的微栓塞似乎是动脉粥样硬化负担增加和冠状动脉疾病进展加快的指标,与急性生物标志物升高和不良的长期预后相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号